Cell-surface galectin-3 confers resistance to TRAIL by impeding trafficking of death receptors in metastatic colon adenocarcinoma cells

Death Receptor Agonists as a Targeted Therapy for Cancer

(2010) J. Wiezorek et al.   CLINICAL CANCER RESEARCH

Glioma-Associated Cancer-Initiating Cells Induce Immunosuppression

(2010) J. Wei et al.   CLINICAL CANCER RESEARCH

TRAIL receptor signaling and therapeutics

(2010) Junaid Abdulghani et al.   EXPERT OPINION ON THERAPEUTIC TARGETS

Galectin multimerization and lattice formation are regulated by linker region structure

(2010) L. A. Earl et al.   GLYCOBIOLOGY

The Road Less Traveled: Regulation of Leukocyte Migration Across Vascular and Lymphatic Endothelium by Galectins

(2010) Sandra Thiemann et al.   JOURNAL OF CLINICAL IMMUNOLOGY

miR-221&222 Regulate TRAIL Resistance and Enhance Tumorigenicity through PTEN and TIMP3 Downregulation

(2009) Michela Garofalo et al.   CANCER CELL

Death Receptor 5 Internalization Is Required for Lysosomal Permeabilization by TRAIL in Malignant Liver Cell Lines

(2009) Yuko Akazawa et al.   GASTROENTEROLOGY

Knockdown of GnT-Va expression inhibits ligand-induced downregulation of the epidermal growth factor receptor and intracellular signaling by inhibiting receptor endocytosis

(2009) H.-B. Guo et al.   GLYCOBIOLOGY

Inhibition of vimentin or  1 integrin reverts morphology of prostate tumor cells grown in laminin-rich extracellular matrix gels and reduces tumor growth in vivo

(2009) X. Zhang et al.   MOLECULAR CANCER THERAPEUTICS

Galectin–glycan lattices regulate cell-surface glycoprotein organization and signalling: Table 1

(2008) Omai B. Garner et al.   BIOCHEMICAL SOCIETY TRANSACTIONS

To kill a tumor cell: the potential of proapoptotic receptor agonists

(2008) Avi Ashkenazi et al.   JOURNAL OF CLINICAL INVESTIGATION